6 / 6
Volume 9
Journal of Allergy & Therapy
ISSN: 2155-6121
Allergy-Clinical Immunology 2018
October 01-02, 2018
Notes:
conference
series
.com
Page 23
October 01-02, 2018 | Moscow, Russia
12
th
International Conference on
Allergy, Asthma & Clinical Immunology
Glady Gilbert, J Allergy Ther 2018, Volume 9
DOI: 10.4172/2155-6121-C2-008
Allergic rhinosinusitis treated by a sublingual nano-immunotherapy
F
or a very long time the so-called modern medicine has been exerting its therapeutic effects through inhibiting actions. It
is, with a closer look, anti-everything! We offer a different model, called the Bio Immune(G)ene Medicine, based on the
connectivity and regulation of the pathophysiological processes affecting cells in a given disease. It is thus a biomimetic method
aiming at being as close as possible to the molecular processes involved in a pathological state at several levels, with a strong focus
on epigenetic regulation by using numerous microRNAs. To this end, a strict approach at the biological level is necessary, in order
to highlight as many factors involved in the disease as possible and then be able to introduce a regulatory treatment. To perform
this, we have at our disposal a nanotherapy administered sublingually, in order to facilitate the transmission of the ultra-low
molecular doses to the immunocompetent cells, which are present in large numbers in the oropharyngeal mucosa. This kind of
therapeutic approach is very-well suited for allergic diseases such as rhinosinusitis. We will try to show in this presentation how
the identification and validation of some pathophysiological processes can lead to a very effective therapy with no side-effect,
relying only on regulation mechanisms at both the molecular and cellular levels, applied in this case to allergic rhinosinusitis.
Biography
Glady Gilbert has graduated Medical School in 1977. Through his work and encounters, he then developed interest and expertise in immunology and immunogenetics
that lead him to nanomedicine and nanobiotechnology. He thus became in 2010 the creator of the Bio Immune(G)ene Medicine and Director of EBMA, the European
association responsible for communication and trainings in this field. He has participated in numerous international congresses in immuno-allergology, infectiology and
oncology and is the author of several publications on nano-biotherapy in different journals.
info@ebma-europe.comGlady Gilbert
European Bio Immune(G)ene Medicine Association, France